High cytoplasmic expression of MAGE-A9 was observed in 36.72% (47/128) of EOC tumors compared with only 6.25% (2/32) of benign tumors and 3.13% (1/32) of borderline ovarian tumors. This evidence concerns the gene MAGEA9 and benign neoplasm.